Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CATARACT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CATARACT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CATARACT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL ANALYSIS CATARACT MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR CATARACT MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR CATARACT MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR CATARACT MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR CATARACT MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
14 REIMBURSEMENT FRAMEWORK
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
17 GLOBAL CATARACT MARKET, BY TYPE
17.1 OVERVIEW
17.2 DIAGNOSIS
17.2.1 VISUAL ACUITY TEST
17.2.2 SLIT-LAMP EXAMINATION
17.2.3 RETINAL EXAM
17.2.4 TONOMETRY TEST
17.2.5 OTHERS
17.3 TREATMENT
17.3.1 NUCLEAR SCLEROTIC CATARACTS, BY TREATMENT PRODUCTS
17.3.1.1. INTRAOCULAR LENS (IOL)
17.3.1.1.1. MONOFOCAL IOL
17.3.1.1.1.1 HYDROPHILLIC MONOFOCAL LENS
17.3.1.1.1.2 HYDROPHOBIC MONOFOCAL LENS
17.3.1.1.2. TORIC IOL
17.3.1.1.3. MULTIFOCAL IOL
17.3.1.1.4. MONOVISION
17.3.1.1.5. OTHERS
17.3.1.2. OPHTHALMIC VISCOELASTIC DEVICE
17.3.1.2.1. COHESIVE OVD
17.3.1.2.2. DISPERSIVE OVD
17.3.1.3. FEMTOSECOND LASER EQUIPMENT, BY BRAND
17.3.1.3.1. INTRALASE
17.3.1.3.2. VISUMAX
17.3.1.3.3. FEMTO LDV
17.3.1.3.4. FEMTEC
17.3.1.3.5. OTHERS
17.3.1.4. OTHERS
17.3.2 CORTICAL CATARACTS, BY TREATMENT PRODUCTS
17.3.2.1. INTRAOCULAR LENS (IOL)
17.3.2.1.1. MONOFOCAL IOL
17.3.2.1.1.1 HYDROPHILLIC MONOFOCAL LENS
17.3.2.1.1.2 HYDROPHOBIC MONOFOCAL LENS
17.3.2.1.2. TORIC IOL
17.3.2.1.3. MULTIFOCAL IOL
17.3.2.1.4. MONOVISION
17.3.2.1.5. OTHERS
17.3.2.2. OPHTHALMIC VISCOELASTIC DEVICE
17.3.2.2.1. COHESIVE OVD
17.3.2.2.2. DISPERSIVE OVD
17.3.2.3. FEMTOSECOND LASER EQUIPMENT, BY BRAND
17.3.2.3.1. INTRALASE
17.3.2.3.2. VISUMAX
17.3.2.3.3. FEMTO LDV
17.3.2.3.4. FEMTEC
17.3.2.3.5. OTHERS
17.3.2.4. OTHERS
17.3.3 POSTERIOR SUBCAPSULAR CATARACTS, BY TREATMENT PRODUCTS
17.3.3.1. INTRAOCULAR LENS (IOL)
17.3.3.1.1. MONOFOCAL IOL
17.3.3.1.1.1 HYDROPHILLIC MONOFOCAL LENS
17.3.3.1.1.2 HYDROPHOBIC MONOFOCAL LENS
17.3.3.1.2. TORIC IOL
17.3.3.1.3. MULTIFOCAL IOL
17.3.3.1.4. MONOVISION
17.3.3.1.5. OTHERS
17.3.3.2. OPHTHALMIC VISCOELASTIC DEVICE
17.3.3.2.1. COHESIVE OVD
17.3.3.2.2. DISPERSIVE OVD
17.3.3.3. FEMTOSECOND LASER EQUIPMENT, BY BRAND
17.3.3.3.1. INTRALASE
17.3.3.3.2. VISUMAX
17.3.3.3.3. FEMTO LDV
17.3.3.3.4. FEMTEC
17.3.3.3.5. OTHERS
17.3.4 MEDICATIONS
17.3.4.1. MYDRIATICS
17.3.4.1.1. PHENYLEPHRINE OPHTHALMIC
17.3.4.1.2. TROPICAMIDE
17.3.4.1.3. OTHERS
17.3.4.2. NONSTEROIDAL ANTI-INFLAMMATORY OPHTHALMICS
17.3.4.2.1. NEPAFENAC OPHTHALMIC
17.3.4.2.2. BROMFENAC OPHTHALMIC
17.3.4.2.3. OTHERS
17.3.4.3. COMBINATION OPHTHALMICS
17.3.4.3.1. KETOROLAC/PHENYLEPHRINE OPHTHALMIC
17.3.4.3.2. OTHERS
17.3.4.4. CORTICOSTEROIDS
17.3.4.4.1. PREDNISOLONE ACETATE 1%
17.3.4.4.2. DEXAMETHASONE OPHTHALMIC
17.3.4.4.3. DIFLUPREDNATE OPHTHALMIC
17.3.4.4.4. LOTEPREDNOL OPHTHALMIC
17.3.4.4.5. OTHERS
17.3.4.5. ANTIBIOTICS
17.3.4.5.1. CIPROFLOXACIN OPHTHALMIC
17.3.4.5.2. MOXIFLOXACIN OPHTHALMIC
17.3.4.5.3. BESIFLOXACIN OPHTHALMIC
17.3.4.5.4. LEVOFLOXACIN OPHTHALMIC
17.3.4.5.5. ERYTHROMYCIN OPHTHALMIC
17.3.4.5.6. OTHERS
17.3.5 SURGERY
17.3.5.1. INCISION SURGERY
17.3.5.1.1. SMALL
17.3.5.1.2. LARGE
17.3.5.2. PHACOEMULSIFICATION
17.3.5.3. EXTRACAPSULAR CATARACT EXTRACTION
17.3.5.4. FEMTOSECOND LASER SURGERY
17.3.5.5. OTHERS
18 GLOBAL CATARACT MARKET, BY GENDER
18.1 OVERVIEW
18.2 MALE
18.2.1 PEDIATRIC
18.2.2 ADULT
18.2.3 GERIATRIC
18.3 FEMALE
18.3.1 PEDIATRIC
18.3.2 ADULT
18.3.3 GERIATRIC
19 GLOBAL CATARACT MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS
19.2.1 BY TYPE
19.2.1.1. PRIVATE
19.2.1.2. PUBLIC
19.2.2 BY LEVEL
19.2.2.1. TIER 1
19.2.2.2. TIER 2
19.2.2.3. TIER 3
19.3 OPHTHALMIC CLINICS
19.4 AMBULATORY SURGICAL CENTERS
19.5 ACADEMIC AND RESEARCH INSTITUTES
19.6 OTHERS
20 GLOBAL CATARACT MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.3.1 ONLINE SALES
20.3.2 OFFLINE SALES
20.4 OTHERS
21 GLOBAL CATARACT MARKET, BY GEOGRAPHY
GLOBAL CATARACT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
21.1 NORTH AMERICA
21.1.1 U.S.
21.1.2 CANADA
21.1.3 MEXICO
21.2 EUROPE
21.2.1 GERMANY
21.2.2 FRANCE
21.2.3 U.K.
21.2.4 HUNGARY
21.2.5 LITHUANIA
21.2.6 AUSTRIA
21.2.7 IRELAND
21.2.8 NORWAY
21.2.9 POLAND
21.2.10 ITALY
21.2.11 SPAIN
21.2.12 RUSSIA
21.2.13 TURKEY
21.2.14 NETHERLANDS
21.2.15 SWITZERLAND
21.2.16 REST OF EUROPE
21.3 ASIA-PACIFIC
21.3.1 JAPAN
21.3.2 CHINA
21.3.3 SOUTH KOREA
21.3.4 INDIA
21.3.5 AUSTRALIA
21.3.6 SINGAPORE
21.3.7 THAILAND
21.3.8 MALAYSIA
21.3.9 INDONESIA
21.3.10 PHILIPPINES
21.3.11 VIETNAM
21.3.12 REST OF ASIA-PACIFIC
21.4 SOUTH AMERICA
21.4.1 BRAZIL
21.4.2 ARGENTINA
21.4.3 PERU
21.4.4 REST OF SOUTH AMERICA
21.5 MIDDLE EAST AND AFRICA
21.5.1 SOUTH AFRICA
21.5.2 GLOBAL
21.5.3 UAE
21.5.4 EGYPT
21.5.5 KUWAIT
21.5.6 ISRAEL
21.5.7 REST OF MIDDLE EAST AND AFRICA
21.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
22 GLOBAL CATARACT MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL CATARACT MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL CATARACT MARKET, COMPANY PROFILE
24.1 JOHNSON & JOHNSON, INC.
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 BAUSCH & LOMB INCORPORATED.
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 OCULENTIS MEDICAL PVT. LTD
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 NIDEK CO., LTD
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.5 CARL ZEISS MEDITECH AG
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 ABBOTT
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 ESSILOR
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 ALCON INC
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 STAAR SURGICAL
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 OMNI LENS PVT. LTD.
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 HOYA MEDICAL SINGAPORE PTE. LTD
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 LENSAR
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 AAREN LABS INC.
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 AKKOLENS CLINICAL BV
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 ALSANZA MEDIZINTECHNIK UND PHARMA GMBH.
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 1STQ DEUTSCHLAND GMBH
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 BVI
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
24.18 RAYNER GROUP
24.18.1 COMPANY OVERVIEW
24.18.2 REVENUE ANALYSIS
24.18.3 GEOGRAPHIC PRESENCE
24.18.4 PRODUCT PORTFOLIO
24.18.5 RECENT DEVELOPMENTS
24.19 HUMANOPTICS HOLDING AG
24.19.1 COMPANY OVERVIEW
24.19.2 REVENUE ANALYSIS
24.19.3 GEOGRAPHIC PRESENCE
24.19.4 PRODUCT PORTFOLIO
24.19.5 RECENT DEVELOPMENTS
24.2 TOPCON HEALTHCARE SOLUTIONS
24.20.1 COMPANY OVERVIEW
24.20.2 REVENUE ANALYSIS
24.20.3 GEOGRAPHIC PRESENCE
24.20.4 PRODUCT PORTFOLIO
24.20.5 RECENT DEVELOPMENTS
24.21 PRECISION LENS
24.21.1 COMPANY OVERVIEW
24.21.2 REVENUE ANALYSIS
24.21.3 GEOGRAPHIC PRESENCE
24.21.4 PRODUCT PORTFOLIO
24.21.5 RECENT DEVELOPMENTS
24.22 AUROLABS
24.22.1 COMPANY OVERVIEW
24.22.2 REVENUE ANALYSIS
24.22.3 GEOGRAPHIC PRESENCE
24.22.4 PRODUCT PORTFOLIO
24.22.5 RECENT DEVELOPMENTS
24.23 ZEIMER OPHTHALMIC SYSTEMS
24.23.1 COMPANY OVERVIEW
24.23.2 REVENUE ANALYSIS
24.23.3 GEOGRAPHIC PRESENCE
24.23.4 PRODUCT PORTFOLIO
24.23.5 RECENT DEVELOPMENTS
24.24 HANITA LENSES
24.24.1 COMPANY OVERVIEW
24.24.2 REVENUE ANALYSIS
24.24.3 GEOGRAPHIC PRESENCE
24.24.4 PRODUCT PORTFOLIO
24.24.5 RECENT DEVELOPMENTS
24.25 EYEKON MEDICAL INC
24.25.1 COMPANY OVERVIEW
24.25.2 REVENUE ANALYSIS
24.25.3 GEOGRAPHIC PRESENCE
24.25.4 PRODUCT PORTFOLIO
24.25.5 RECENT DEVELOPMENTS
24.26 APOLLO OPTICAL SYSTEMS
24.26.1 COMPANY OVERVIEW
24.26.2 REVENUE ANALYSIS
24.26.3 GEOGRAPHIC PRESENCE
24.26.4 PRODUCT PORTFOLIO
24.26.5 RECENT DEVELOPMENTS
24.27 RXSIGHT
24.27.1 COMPANY OVERVIEW
24.27.2 REVENUE ANALYSIS
24.27.3 GEOGRAPHIC PRESENCE
24.27.4 PRODUCT PORTFOLIO
24.27.5 RECENT DEVELOPMENTS
24.28 CARE GROUP
24.28.1 COMPANY OVERVIEW
24.28.2 REVENUE ANALYSIS
24.28.3 GEOGRAPHIC PRESENCE
24.28.4 PRODUCT PORTFOLIO
24.28.5 RECENT DEVELOPMENTS
24.29 HAAG STREIT HOLDING
24.29.1 COMPANY OVERVIEW
24.29.2 REVENUE ANALYSIS
24.29.3 GEOGRAPHIC PRESENCE
24.29.4 PRODUCT PORTFOLIO
24.29.5 RECENT DEVELOPMENTS
24.3 VALEANT PHARMACEUTICALS
24.30.1 COMPANY OVERVIEW
24.30.2 REVENUE ANALYSIS
24.30.3 GEOGRAPHIC PRESENCE
24.30.4 PRODUCT PORTFOLIO
24.30.5 RECENT DEVELOPMENTS
24.31 GLAUKOS CORPORATION
24.31.1 COMPANY OVERVIEW
24.31.2 REVENUE ANALYSIS
24.31.3 GEOGRAPHIC PRESENCE
24.31.4 PRODUCT PORTFOLIO
24.31.5 RECENT DEVELOPMENTS
24.32 ELLEX
24.32.1 COMPANY OVERVIEW
24.32.2 REVENUE ANALYSIS
24.32.3 GEOGRAPHIC PRESENCE
24.32.4 PRODUCT PORTFOLIO
24.32.5 RECENT DEVELOPMENTS
24.33 NOVARTIS AG
24.33.1 COMPANY OVERVIEW
24.33.2 REVENUE ANALYSIS
24.33.3 GEOGRAPHIC PRESENCE
24.33.4 PRODUCT PORTFOLIO
24.33.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
